Rise of GLP-1 drugs brings substantial litigation risk: DAC Beachcroft
Law firm DAC Beachcroft has warned of a surge in product liability claims following the rise of the popular glucagon-like peptide 1 receptor agonist (or GLP-1), a drug used to manage obesity. Despite the health benefits of drugs like Ozempic and Wegowy, their rapid adoption has triggered a wave of legal challenges in the United…